Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Debio 1562 + Rituximab in R/R DLBCL and NHL
NCT02564744Phase 2Completed
- Sponsor
- Debiopharm
- Start
- Jun 2016
- Primary completion
- Jan 2021
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 9
01
Overview
A Phase 2 trial of naratuximab emtansine in diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), marginal zone lymphoma (MZL), mantle cell lymphoma (MCL), sponsored by Debiopharm. Started Jun 2016; status: completed.
02
Drugs
naratuximab emtansine
03
Conditions
diffuse large B-cell lymphoma (DLBCL)follicular lymphoma (FL)marginal zone lymphoma (MZL)mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on NCT02564744.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02564744.